1. in diabetic patients with mixed dyslipidemia
PCSK9 inhibition vs. usual lipid-lowering therapy on top of maximal statin therapy
in diabetic patients with mixed dyslipidemia
Sub-study of the ODYSSEY DM-DYSLIPIDEMIA randomized trial
UC: usual care including fenofibrate, omega-3-fatty acids, ezetimibe, or nicotinic acid
PCSK9: proprotein convertase subtilisin-kexin type 9; HDL-c: high-density lipoprotein cholesterol; LDL-c low-density lipoprotein cholesterol; TG: triglycerides;
Ray KK. Diab Obes Metabol 2018